HERITAGE PHARMACEUTICALS INC.

Heritage Pharmaceuticals Inc. specializes in the manufacturing of pharmaceutical preparations, focusing on the formulation, production, and quality-controlled scaling of finished dosage forms for government healthcare programs. Their technical expertise lies in adhering to cGMP standards for drug manufacturing, ensuring batch consistency, regulatory compliance, and supply chain integrity for federally procured medications. The company’s operations emphasize precision in active pharmaceutical ingredient processing, packaging validation, and documentation systems required under FDA and VA procurement protocols. While their award history is limited, the most recent contract under Public Law 2025 Pricing Updates suggests direct involvement in aligning product pricing structures with federal reimbursement frameworks, indicating a nuanced understanding of statutory pricing mechanisms and pharmaceutical cost containment policies. The Department of Veterans Affairs is the sole agency represented in their contract history, pointing to a focused relationship supporting VA’s pharmaceutical supply chain for veteran care. This engagement likely involves the production of oral solids, injectables, or other standardized medications used in VA medical centers, with an emphasis on reliability, regulatory traceability, and timely delivery to federal distribution networks. Heritage Pharmaceuticals operates within NAICS 325412, which encompasses the full lifecycle of prescription and over-the-counter drug manufacturing—from active ingredient blending to final packaging. Their market positioning is that of a niche manufacturer serving public health mandates, particularly in sectors requiring strict adherence to federal pharmaceutical regulations. As a 2L entity based in East Brunswick, New Jersey, the company is structured as a small to mid-sized manufacturer without federal certifications such as 8(a), HUBZone, or WOSB. Their geographic presence is localized, but their operational footprint is aligned with the federal pharmaceutical supply chain, positioning them as a compliant, regionally situated producer for government healthcare procurement needs.